Sanofi is currently facing a shortage of its drug for Pompe disease, which is affecting patients' ability to receive essential treatments. This situation is critical as it not only highlights the challenges in the pharmaceutical supply chain but also raises questions about Sanofi's operational efficiency and its capacity to fulfill patient needs.
The shortage could lead to increased scrutiny from healthcare providers and regulators, potentially affecting Sanofi's reputation and market share in the rare disease segment. Investors should monitor how the company addresses this issue and the long-term implications it may have on its sales and growth prospects